New hope for Hard-to-Treat breast cancer: drug combo trial launches
NCT ID NCT04468061
First seen Jan 08, 2026 · Last updated Apr 30, 2026 · Updated 21 times
Summary
This study tests whether adding pembrolizumab to sacituzumab govitecan helps control advanced triple-negative breast cancer that is PD-L1-negative. About 110 adults with metastatic disease will receive either the combination or sacituzumab alone. The goal is to see which approach delays cancer growth longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
DF/BWCC in Clinical Affiliation with South Shore Hospital
RECRUITINGSouth Weymouth, Massachusetts, 02190, United States
Contact Email: •••••@•••••
Contact
-
DFCI @ Foxborough
RECRUITINGFoxborough, Massachusetts, 02035, United States
Contact Email: •••••@•••••
Contact
-
DFCI @ Milford Regional Hospital
RECRUITINGMilford, Massachusetts, 01757, United States
Contact Email: •••••@•••••
Contact
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Eastern Maine Medical Center
RECRUITINGBrewer, Maine, 04412, United States
Contact Email: •••••@•••••
Contact
-
Medical University of South Carolina
RECRUITINGCharleston, South Carolina, 29425, United States
Contact Email: •••••@•••••
Contact
Contact
-
Miami Cancer Institute at Baptist Health
RECRUITINGPlantation, Florida, 33324, United States
Contact Email: •••••@•••••
Contact
-
Miami Cancer Institute at Baptist Health (Kendall)
RECRUITINGMiami, Florida, 33176, United States
Contact Email: •••••@•••••
Contact
-
Ohio State University Medical Center
RECRUITINGColumbus, Ohio, 43212, United States
Contact Email: •••••@•••••
Contact
-
Sarah Cannon Research Institute
RECRUITINGChattanooga, Tennessee, 37404, United States
Contact Email: •••••@•••••
Contact
-
Stamford Hospital
RECRUITINGStamford, Connecticut, 06904, United States
Contact Email: •••••@•••••
Contact
-
The Christ Hospital Cancer Center
RECRUITINGCincinnati, Ohio, 45219, United States
Contact Email: •••••@•••••
Contact
-
The University of North Carolina at Chapel Hill
RECRUITINGChapel Hill, North Carolina, 27599, United States
Contact Email: •••••@•••••
Contact
-
University of Chicago Medical Center
RECRUITINGChicago, Illinois, 60637, United States
Contact Email: •••••@•••••
Contact
-
University of Pennsylvania-Abramson Cancer Center
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.